93/590/EC: Commission Decision of 5 November 1993 for the purchase by the Community of foot-and-mouth disease antigens within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines

• Articles: 4

Article 1

1. The Community shall purchase five million doses of each of the following strains of foot-and-mouth disease antigen:

- A5 European,

- A22 Middle East,

- O1 Middle East,

- O1 European,

up to a maximum cost of ECU 4 065 million.

2. The antigen mentioned in paragraph 1 shall be supplied by Rhône-Mérieux, Pirbright Laboratory, Ash Road, Surrey, United Kingdom.

Article 2

1. To meet the objectives of Article 1, the Commission shall conclude a contract, in the name of the European Community, with Rhône-Mérieux.

2. The Director General of Directorate General for Agriculture shall be authorized to sign the contract on behalf of the Commission of the European Communities.

3. Payment to Rhône-Mérieux shall be made in accordance with the terms of the contract provided for in paragraph 1.

Article 3

The antigen shall be divided between the four antigen banks as follows:

(a) Bayer, Cologne and the Institute for Animal health, Pirbright: 2,5 million doses of each of O1 European strain and A5 in each bank;

(b) LNPB, Lyon and 1ZP, Brescia: 2,5 million doses of each of O1 Middle East strain and A22 in each bank.

Article 4

This Decision is addressed to the Member States.

Done at Brussels, 5 November 1993.

For the Commission

René STEICHEN

Member of the Commission

(1) OJ No L 224, 18. 8. 1990, p. 19.

(2) OJ No L 203, 13. 8. 1993, p. 34.

(3) OJ No L 368, 31. 12. 1991, p. 21.

(4) OJ No L 94, 28. 4. 1970, p. 13.